Literature DB >> 27084031

The hepatitis delta virus: Replication and pathogenesis.

Camille Sureau1, Francesco Negro2.   

Abstract

Hepatitis delta virus (HDV) is a defective virus and a satellite of the hepatitis B virus (HBV). Its RNA genome is unique among animal viruses, but it shares common features with some plant viroids, including a replication mechanism that uses a host RNA polymerase. In infected cells, HDV genome replication and formation of a nucleocapsid-like ribonucleoprotein (RNP) are independent of HBV. But the RNP cannot exit, and therefore propagate, in the absence of HBV, as the latter supplies the propagation mechanism, from coating the HDV RNP with the HBV envelope proteins for cell egress to delivery of the HDV virions to the human hepatocyte target. HDV is therefore an obligate satellite of HBV; it infects humans either concomitantly with HBV or after HBV infection. HDV affects an estimated 15 to 20 million individuals worldwide, and the clinical significance of HDV infection is more severe forms of viral hepatitis--acute or chronic--, and a higher risk of developing cirrhosis and hepatocellular carcinoma in comparison to HBV monoinfection. This review covers molecular aspects of HDV replication cycle, including its interaction with the helper HBV and the pathogenesis of infection in humans.
Copyright © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chronic hepatitis; Cirrhosis; Hepatocellular carcinoma; Viroids

Mesh:

Substances:

Year:  2016        PMID: 27084031     DOI: 10.1016/j.jhep.2016.02.013

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  81 in total

Review 1.  HBV/HDV Coinfection: A Challenge for Therapeutics.

Authors:  Christopher Koh; Ben L Da; Jeffrey S Glenn
Journal:  Clin Liver Dis       Date:  2019-05-24       Impact factor: 6.126

Review 2.  A 360° view of circular RNAs: From biogenesis to functions.

Authors:  Jeremy E Wilusz
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-04-14       Impact factor: 9.957

Review 3.  Current advances in the elimination of hepatitis B in China by 2030.

Authors:  Shuye Zhang; Fusheng Wang; Zheng Zhang
Journal:  Front Med       Date:  2017-11-23       Impact factor: 4.592

Review 4.  Viral hepatitis and hepatocellular carcinoma: etiology and management.

Authors:  Philippe J Zamor; Andrew S deLemos; Mark W Russo
Journal:  J Gastrointest Oncol       Date:  2017-04

5.  The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection.

Authors:  Elizabeth C Townsend; Grace Y Zhang; Rabab Ali; Marian Firke; Mi Sun Moon; Ma Ai Thanda Han; Benjamin Fram; Jeffrey S Glenn; David E Kleiner; Christopher Koh; Theo Heller
Journal:  J Gastroenterol Hepatol       Date:  2019-02-25       Impact factor: 4.029

6.  Hepatitis delta infection in Italian patients: towards the end of the story?

Authors:  Tommaso Stroffolini; Evangelista Sagnelli; Caterina Sagnelli; Maurizio Russello; Massimo De Luca; Floriano Rosina; Bruno Cacopardo; Giuseppina Brancaccio; Caterina Furlan; Giovanni Battista Gaeta; Anna Licata; Piero Luigi Almasio
Journal:  Infection       Date:  2016-11-05       Impact factor: 3.553

7.  Impact of nucleic acid extraction platforms on hepatitis virus genome detection.

Authors:  Matthew D Pauly; Saleem Kamili; Tonya M Hayden
Journal:  J Virol Methods       Date:  2019-08-13       Impact factor: 2.014

8.  Hepatitis D infection: from initial discovery to current investigational therapies.

Authors:  Ben L Da; Theo Heller; Christopher Koh
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-06-23

9.  Nucleic Acid Polymers Are Active against Hepatitis Delta Virus Infection In Vitro.

Authors:  Frauke Beilstein; Matthieu Blanchet; Andrew Vaillant; Camille Sureau
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

Review 10.  Pathogenesis of and New Therapies for Hepatitis D.

Authors:  Christopher Koh; Theo Heller; Jeffrey S Glenn
Journal:  Gastroenterology       Date:  2018-10-18       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.